Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Bertagna

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept studyXavier Bertagna, Rosario Pivonello, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2006
Prognostic parameters of metastatic adrenocortical carcinomaGuillaume Assié, Guillemette Antoni, Frédérique Tissier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumorsRossella Libé, Amato Fratticci, Joel Coste, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2011
Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approachOlivia Barreau, Aurélien de Reynies, Hortense Wilmot-Roussel, et al.
European Journal of Endocrinology|December 19, 2013
Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomasBruno Ragazzon, Rossella Libé, Guillaume Assié, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2010
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancersSébastien Gaujoux, Stéphane Pinson, Anne-Paule Gimenez-Roqueplo, et al.
The Journal of Clinical Endocrinology and Metabolism|October 25, 2012
Identification of a CpG island methylator phenotype in adrenocortical carcinomasOlivia Barreau, Guillaume Assié, Hortense Wilmot-Roussel, et al.
Cancer Research|September 6, 2005
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumorsFrédérique Tissier, Catherine Cavard, Lionel Groussin, et al.
European Journal of Endocrinology|July 5, 2007
Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomasLaure Cazabat, Rossella Libè, Karine Perlemoine, et al.
European Journal of Endocrinology|August 6, 2015
The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomasClaire Chambre, Emily McMurray, Camille Baudry, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Endocrinology and Metabolism|January 16, 2014
LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept studyXavier Bertagna, Rosario Pivonello, Maria Fleseriu, et al.
The Journal of Clinical Endocrinology and Metabolism|October 26, 2006
Prognostic parameters of metastatic adrenocortical carcinomaGuillaume Assié, Guillemette Antoni, Frédérique Tissier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumorsRossella Libé, Amato Fratticci, Joel Coste, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2011
Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approachOlivia Barreau, Aurélien de Reynies, Hortense Wilmot-Roussel, et al.
European Journal of Endocrinology|December 19, 2013
Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomasBruno Ragazzon, Rossella Libé, Guillaume Assié, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2010
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancersSébastien Gaujoux, Stéphane Pinson, Anne-Paule Gimenez-Roqueplo, et al.
The Journal of Clinical Endocrinology and Metabolism|October 25, 2012
Identification of a CpG island methylator phenotype in adrenocortical carcinomasOlivia Barreau, Guillaume Assié, Hortense Wilmot-Roussel, et al.
Cancer Research|September 6, 2005
Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumorsFrédérique Tissier, Catherine Cavard, Lionel Groussin, et al.
European Journal of Endocrinology|July 5, 2007
Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomasLaure Cazabat, Rossella Libè, Karine Perlemoine, et al.
European Journal of Endocrinology|August 6, 2015
The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomasClaire Chambre, Emily McMurray, Camille Baudry, et al.
Pageof 13